Teen sleep secrets: could your bedtime predict depression?
NCT ID NCT05691439
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how sleep duration and timing, along with stressful life events, are linked to depression and loss of interest in activities (anhedonia) in teenagers aged 14-18. Researchers will monitor 150 high school students using questionnaires, brain scans, and stress tests. The goal is to better understand these connections to help design future prevention programs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2023
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
14 to 18 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. 14-18 years of age 2. Currently in high school 3. short and late sleep (weekday sleep duration ≤ 7 h and bedtime ≥ 22:30 (10:30 pm); n=100) or long and early sleep (weekday sleep duration \> 7 hours and bedtime ≤ 22:30 (10:30 pm); n=50), indexed by the Munich Chronotype Questionnaire 4. Lifetime stressful event frequency ≥ 2 on the Stress and Adversity Inventory (STRAIN) Screener 5. Depressive symptom severity t-score greater than or equal to 45 on the Patient Reported Outcomes (PROMIS) Depression scale 6. English language fluency Exclusion Criteria: 1. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for current moderate to severe alcohol/substance use disorder (≥4 symptoms); 2. Current clinician-provided diagnosis of narcolepsy or idiopathic hypersomnia; 3. Lifetime diagnosis of bipolar or schizophrenia spectrum disorder; 4. Certain medical conditions (e.g., serious neurological disorder, heart failure or serious heart trouble, history of head injury with unconsciousness \> 5 minutes); 5. Conditions that are contraindicated for magnetic resonance imaging (MRI; e.g., ferrous metal in the body); 6. Positive screen for participant-reported eye disease, epilepsy, or photosensitizing medications that are contraindicated during the manipulation condition when bright light is administered (e.g., psychiatric neuroleptic drugs \[e.g., phenothiazine\], psoralen drugs, antiarrhythmic drugs \[e.g., amiodarone\], antimalarial and antirheumatic drugs, porphyrin drugs used in photodynamic treatment of skin diseases); 7. Use of melatonin if participant is not willing to discontinue use for the duration of the study. We will schedule around (i.e., delay appointments as needed) to avoid the timeframe of the following events: 1. urgent suicide risk, defined by moderate/severe risk per Columbia Suicide Severity Rating Scale (CSSRS) and clinician determination that current risk requires immediate action; 2. travel across two or more time zones within the month prior to the overnight study visits; 3. beginning or ending a prescribed medication within 2 months of the observational study; 4. prescribed medication dose changes within the timeframe calculated as 5x the drug's half-life \[the time to reach pharmacokinetic steady-state\] before the initiation of the observational or experimental studies; 5. anticipated change in prescribed medications or medication dosing during the observational or experimental studies; 6. current symptoms of airborne infectious illness prior to laboratory visits. Participants with positive breathalyzer screen (blood alcohol level \> .02) will be rescheduled for an alternative overnight visit date.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Depression in adolescence are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Oregon
RECRUITINGEugene, Oregon, 97403, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a website help young people understand depression?
- Does blue light calm the depressed brain? a scan study investigates
- Can a school program turn the tide on teen suicide?
- Magnetic brain pulses could offer Drug-Free hope for teen depression
- Could a virtual activity-based therapy lift teen depression?
- Could a blood test spot teen suicide risk?